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Summary
Obsessive-compulsive disorder (OCD) is one of the most 
difficult additional diagnoses to manage in patients with 
bipolar disorder (BD) since the gold standard treatment 
for one disease (antidepressants for OCD) can worsen 
the other. This case report describes the efficacy of 
aripiprazole augmentation as maintenance therapy in 
a young patient with comorbid BD-OCD. Our patient 
presented complete remission of affective and obsessive-
compulsive symptoms with remarkable improvement 
in social and occupational functioning for 24 months. 
Adverse drug reactions were not severe enough to result 
in drug discontinuation. In consideration of the important 
nosological, clinical and therapeutic implications, future 
research efforts may lead to more grounded guidelines, 
which are greatly needed in patients with comorbid BD-
OCD.
InTroduCTIon
Obsessive-compulsive disorder (OCD) is one 
of the most difficult additional diagnoses 
to manage in patients with bipolar disorder 
(BD), and the meaning of this comorbidity 
has not been clarified yet.
The results from our meta-analysis showed 
higher comorbidity rates in youths (24.2%, 
95% CI 10.36 to 41.60, n=345, z=−9.5) 
compared with adults (13.56%, 95% CI 10.4 to 
16.25, n=4539),1 with the majority of patients 
who experienced the onset of OCD prior 
to the onset of BD.2 Patients with BD-OCD 
presented higher prevalence of family history 
for mood disorders and lower prevalence of 
family history for OCD than patients without 
BD-OCD.3 Moreover, compared with non-co-
morbid subjects, patients with BD-OCD have 
a more episodic course of obsessive-com-
pulsive symptoms, typically with worsening 
during depression and improvement during 
mania/hypomania.4
BD-OCD comorbidity has important clin-
ical implications: how to treat the comor-
bidity since the main treatment (serotonin 
reuptake inhibitors, SRIs) for OCD can 
worsen BD?5
We present the case of a patient with severe 
BD who developed obsessive-compulsive 
symptoms during treatment with clozapine.
CaSe hISTory
The patient is a 25-year-old Caucasian unmar-
ried man with a positive family history of 
recurrent depression.
When he was 20, he experienced a manic 
episode with mood-incongruent psychotic 
features (Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition (DSM-5) 
criteria) and he was treated with lithium 
carbonate 900 mg/day and olanzapine 25 
mg/day. Olanzapine was gradually decreased 
and lithium was continued with mood stabil-
isation and remission of affective symptoms.
One year later, he developed a severe mixed 
episode with similar paranoid delusions. His 
therapy was modified to lithium carbonate 
900 mg/day and risperidone 4 mg/day; 
however, paranoid and affective symptoms 
were only partially controlled.
Almost 1 year later, manic symptoms and 
paranoid delusions increased prominently. 
Risperidone 37.5 mg intramuscular every 2 
weeks was added to lithium carbonate 900 
mg/day. Risperidone was stopped because of 
adverse drug reactions (hyperprolactinemia 
and weight gain), and his therapy was modi-
fied to clozapine 300 mg/day and lithium 
carbonate 900 mg/day.
However, as clozapine was gradually 
increased to 450 mg/day, the patient started 
presenting sexual obsessions with intrusive 
thoughts that met DSM-5 criteria for OCD. 
He was treated with paroxetine 30 mg/day 
without satisfactory control of obsessive-com-
pulsive symptoms.
After 8 weeks, he developed a new manic 
episode. Paroxetine and clozapine were 
stopped and the addition of aripiprazole 
30 mg/day to lithium carbonate, gradu-
ally decreased to 15 mg/day, helped to 
achieve mood stabilisation and remission 
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of obsessive-compulsive symptoms for the following 24 
months.
No further hospitalisation was needed and the patient 
presented a remarkable improvement in social and occu-
pational functioning.
dISCuSSIon
This case report describes the efficacy of aripiprazole 
augmentation in BD-OCD maintenance therapy. Our 
patient presented complete remission of obsessive-com-
pulsive symptoms and mood stabilisation without further 
hospitalisations.
Aripiprazole is an atypical antipsychotic that acts as a 
partial agonist at the D2 and 5-HT1A receptors, as well as 
an antagonist at 5-HT2A receptor. Recent studies showed 
the efficacy of aripiprazole monotherapy or in addition 
to mood stabilisers in managing acute mania and stabili-
sation phases in BD, and in addition to SRIs in refractory 
OCD. Futhermore, there is evidence that aripiprazole 
augmentation to mood stabilisers, even at low doses, is 
also effective in patients with BD-OCD comorbidity.6
In our case, positive family history for affective disorders, 
improvement of affective and obsessive-compulsive symp-
toms with mood stabilisers and atypical antipsychotics, 
and manic switch induced by antidepressant, support the 
hypothesis of an underlying OCD comorbidity unmasked 
by the use of clozapine to manage treatment-resistant BD.
The results from a recent systematic review showed 
that mood stabilisation should be the first objective in 
patients with apparent BD-OCD, as opposed to imme-
diate treatment with SRIs. Addition of SRI agents seems 
unnecessary in most cases, although it may be needed in 
refractory OCD.7
Progress in this area would serve to shed light on the 
best clinical management of BD-OCD comorbidity. In 
consideration of the important nosological, clinical and 
therapeutic implications, future research efforts may lead 
to more grounded guidelines, which are greatly needed 
in patients with comorbid BD-OCD.
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